Meetings - The ASCO Post

This is Part 3 of ALK-Positive Metastatic NSCLC: Where Are We Now?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Todd Bauer, ...

lung cancer

/ ALK-Positive Metastatic NSCLC: Where Are We Now

First-Line ALK-Positive NSCLC With CNS Metastases at Baseline and CNS Toxicity

This is Part 2 of ALK-Positive Metastatic NSCLC: Where Are We Now?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Todd Bauer, ...

lung cancer

/ ALK-Positive Metastatic NSCLC: Where Are We Now

First-Line ALK-Positive NSCLC With CNS Metastases at Baseline

This is Part 1 of ALK-Positive Metastatic NSCLC: Where Are We Now?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Todd Bauer, ...

ALK-Positive Metastatic NSCLC: Where Are We Now

Second-Line ALK-Positive NSCLC With CNS Progression on First-Line Crizotinib

First-Line ALK-Positive NSCLC With CNS Metastases at Baseline and CNS Toxicity

First-Line ALK-Positive NSCLC With CNS Metastases at Baseline

Impact of ASH Minority Recruitment Initiative on Retaining, Engaging Underrepresented Hematologists

Addition of Hyperthermic Intraperitoneal Chemotherapy to Surgery for Recurrent Ovarian Cancer

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC